ArticleObesity surgery2026
Endoscopic Sleeve Gastroplasty: 6-Year Outcomes in 1,377 Patients.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndoscopic sleeve gastroplasty (ESG) is a minimally invasive endoluminal bariatric procedure, but long-term outcomes beyond 5 years remain limited. This study reports 6-year weight loss, comorbidity outcomes, and safety data from a large single-center cohort.
methodsThis retrospective cohort study included adults undergoing ESG between June 2019 and June 2025 with mean follow up of 3.8 ± 1.4 years. Primary outcomes were percent total weight loss (%TWL) and percent excess weight loss (%EWL) assessed up to 6 years. Secondary outcomes included resolution or improvement of type 2 diabetes mellitus (T2DM), hypertension, obstructive sleep apnea (OSA), and dyslipidemia. Adverse events and revision procedures were recorded. Missing data were handled using multiple imputation by chained equations within an intention-to-treat framework, with sensitivity analyses using non-responder imputation and last-observation-carried-forward methods.
resultsA total of 1,377 patients underwent ESG (mean age 41.5 ± 12.2 years; 53.5% female; baseline BMI 35.2 ± 4.8 kg/m²). Mean %TWL was 21.2% (95% CI 20.8–21.6) at 1 year and 14.4% (95% CI 14.0–14.8) at 6 years. Mean %EWL was 56.9% at 1 year and 43.4% at 6 years. At 6 years, resolution or improvement was observed in T2DM (51.2%), hypertension (65.8%), OSA (89.9%), and dyslipidemia (73.6%). There was no mortality. One patient (0.07%) required operative intervention for bleeding. Revision procedures occurred in 5.7% of patients.
conclusionsThis study shows that ESG produces measurable weight loss and achieves comorbidity improvement through 6 years, with a favourable safety profile and low revision rate. however, prospective comparative studies are needed to define its role relative to surgical and pharmacologic therapies.
Indexed as
Identifiers
41703242What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.